Amazon Facemasks

Paxlovid: Virologic characterization of nirmatrelvir-ritonavir rebound

Health, Infection, Paxlovid, Side Effects, Transmission, Treatment

Symptomatic relapse after nirmatrelvir-ritonavir therapy for early stage COVID-19 infection is  associated with high viral load.”…

We enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis.

Symptomatic relapse after nirmatrelvir-ritonavir therapy for early stage COVID-19 infection is  associated with high viral load and, in a subset of individuals, culturable virus. We identified live virus at up to 11 days after completion of nirmatrelvir-ritonavir therapy (16 days from the pre-treatment PCR test).

By contrast, we recently reported that untreated outpatients infected with the Omicron variant SARS-CoV-2 shed viable virus for a median of 5 days after an initial positive test.

Preprint: Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19

 

 

Paxlovid: Covid-19 infections rebounding a few days after treatment *4 UPDATES*

 

 

 

 

Image by Michal Jarmoluk from Pixabay